柏柏林可以缓解炎症,并通过向DSS诱导的性结肠炎中的肠道微生物群来抑制PLA2-COX-2-PGE2-EP2通路
Hansheng Yu1, Shaobao Zhang2, Ruiming Li3
1School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Shenzhen, 518107, China; Department of Pharmacy, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518107, China.
Biochemical and biophysical research communications
|December 28, 2023
概括
柏柏林通过调节肠道微生物群,抑制PLA2-COX-2-PGE2-EP2通路来缓解性结肠炎 (UC). 这种机制在具有完整肠道微生物群的小鼠中得到证实,而不是在伪无细菌的小鼠中.
科学领域:
- 药理学 药理学是指药理学的学科.
- 微生物学 微生物学
- 胃肠病学 胃肠病学
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠病.
- 柏柏林通过调节肠道微生物群,显示出治疗UC的潜力.
- 连接Berberine的有效性,肠道微生物群和UC的确切机制尚不清楚.
研究的目的:
- 调查Berberine在治疗UC中的机制.
- 阐明肠道微生物群与柏柏林的治疗作用之间的因果关系.
- 确定参与Berberine在UC中的抗炎作用的关键分子通路.
主要方法:
- 使用伪无细菌 (PGF) 的小鼠和DSS诱导的大肠炎模型.
- 进行了16S rRNA基因测序,用于肠道微生物群分析.
- 进行了转录组分析,以确定分子通路.
主要成果:
- 柏柏林改善了肠道微生物群,减少了结肠损伤,并调节了肠道微生物群完整的小鼠的细胞因子配置,但不是PGF小鼠.
- 免疫相关和炎症相关的途径被确定为Berberine的有效性至关重要.
- 柏柏林显著降低了具有完整肠道微生物群的大肠炎小鼠的PGE2,PLA2,COX-2,Ptges,EP2和p-Stat3水平.
结论:
- 柏柏林通过调节肠道微生物群来对UC产生治疗作用.
- 这项研究证实,柏柏林通过肠道微生物群抑制PLA2-COX-2-PGE2-EP2通路,缓解结肠炎症.
- 结果提供了对Berberine在UC中的机制的更深入的理解,支持其临床应用.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
144
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
144
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
444
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
444
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
430
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
430
Peptic Ulcer Disease IV: Management
95
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
95
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
434
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
434
Inflammatory Bowel Disease IV: Pharmacological Management
128
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
128


